GMNN: A Potential Drug Target for Neurodegenerative Diseases (G51053)

Target Name: GMNN

NCBI ID: G51053

GMNN: A Potential Drug Target for Neurodegenerative Diseases

GMNN (Geminin) is a protein that is expressed in the brain and other nervous tissue. It is a potential drug target and has been shown to play a role in a number of neurological and psychiatric conditions, including Alzheimer's disease, Parkinson's disease, and depression.

The search for new drug targets is a constant in the world of medicine. These targets are proteins that are involved in the development and progression of a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. One promising area of research is the study of neurodegenerative diseases, which are characterized by the progressive loss of brain cells and the development of symptoms such as cognitive decline and progressive muscle weakness.

GMNN is one of the proteins that has been identified as a potential drug target in the study of neurodegenerative diseases. It is expressed in the brain and other nervous tissue and is involved in the development and progression of a number of neurological and psychiatric conditions, including Alzheimer's disease, Parkinson's disease, and depression.

One of the key features of GMNN is its role in the formation of neurofibrillary tangles, which are the hallmark of Alzheimer's disease. These tangles are composed of abnormal aggregates of the protein tau and beta-amyloid, which are thought to contribute to the progressive loss of brain cells in the disease. By blocking the activity of GMNN, researchers may be able to reduce the formation of these tangles and potentially slow the progression of Alzheimer's disease.

In addition to its role in the formation of neurofibrillary tangles, GMNN is also involved in the regulation of the immune response. This is important because an imbalance in the immune response has been implicated in the development of a number of neurodegenerative diseases, including Alzheimer's disease. By modulating the immune response, GMNN may be able to reduce the risk of these diseases.

Another potential drug target for GMNN is its role in the regulation of the blood-brain barrier. This is the barrier that separates the brain from the body and is thought to play a key role in the development of neurodegenerative diseases. By manipulating the blood-brain barrier, GMNN may be able to deliver drugs directly to the brain and potentially reduce the risk of side effects.

In addition to its potential drug-targeting properties, GMNN is also of interest to researchers because of its unique structure and biology. Unlike many other proteins, GMNN is not a typical cytoplasmic protein, meaning it does not have a clearly defined cytoplasmic localization in the cell. This is important because it allows researchers to study its behavior in a more detailed and controlled way.

Overall, GMNN is a protein that has the potential to be a drug target for a variety of neurological and psychiatric conditions. Its role in the formation of neurofibrillary tangles and its involvement in the regulation of the immune response and the blood-brain barrier make it an attractive target for researchers. Further studies are needed to fully understand its behavior and its potential as a drug.

Protein Name: Geminin DNA Replication Inhibitor

Functions: Inhibits DNA replication by preventing the incorporation of MCM complex into pre-replication complex (pre-RC) (PubMed:9635433, PubMed:14993212, PubMed:20129055, PubMed:24064211). It is degraded during the mitotic phase of the cell cycle (PubMed:9635433, PubMed:14993212, PubMed:24064211). Its destruction at the metaphase-anaphase transition permits replication in the succeeding cell cycle (PubMed:9635433, PubMed:14993212, PubMed:24064211). Inhibits histone acetyltransferase activity of KAT7/HBO1 in a CDT1-dependent manner, inhibiting histone H4 acetylation and DNA replication licensing (PubMed:20129055). Inhibits the transcriptional activity of a subset of Hox proteins, enrolling them in cell proliferative control (PubMed:22615398)

More Common Targets